Matthew Swiber, MD
Pain Medicine · Morehead City, NCNPI 1730150541
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,406 of the $4,947 with a category attached, or 89.1%. Abbott accounts for 72.4% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2019 at $1,704 and has fallen 50.4% since, to $844 in 2025.
Across 280 payments — averaging $17.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- Pfizer$214
- Daiichi Sankyo Inc.$204
- AbbVie$179
- Collegium Pharmaceutical, Inc.$135
- Boston Scientific$117
- plus $517 from 15 others
What the payments were for
- Travel & lodging$54111%
- Food & beverage$4,40689%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 204 | $3,581 |
| Pfizer | 6 | $214 |
| Daiichi Sankyo Inc. | 20 | $204 |
| AbbVie(2 entities) | 10 | $179 |
| Collegium Pharmaceutical, Inc. | 6 | $135 |
| Boston Scientific | 6 | $117 |
| Arbor Pharmaceuticals, Inc. | 6 | $80 |
| Vertex | 1 | $61 |
| SPR Therapeutics, Inc | 1 | $56 |
| Biodelivery Sciences International, Inc. | 4 | $55 |
| Valinor Pharma, LLC | 2 | $42 |
| Amgen | 2 | $37 |
| MDD US Operations, LLC | 2 | $28 |
| Sentynl Therapeutics, Inc. | 2 | $26 |
| Kaleo, Inc. | 2 | $26 |
| Painteq LLC | 1 | $24 |
| GRT US Holding, Inc. | 1 | $24 |
| Nevro Corp. | 1 | $18 |
| Zyla Life Sciences, Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Pernix Therapeutics Holdings, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,947 in reported general payments places this provider in the 55th percentile of 182 pain medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 23 | $16,717 |
| GraliseGabapentin | 13 | $15,719 |
| OxycontinOxycodone Hcl | 13 | $14,452 |
| Emgality PenGalcanezumab-Gnlm | 11 | $8,022 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 178 | $7,049 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 175 | $6,686 |
| Oxycodone Hcl | 247 | $6,263 |
| MovantikNaloxegol Oxalate | 11 | $4,575 |
| Buprenorphine | 25 | $3,707 |
| Pregabalin | 137 | $3,579 |
| Gabapentin | 190 | $3,127 |
| Diclofenac Sodium | 66 | $2,983 |
| Lidocaine | 19 | $1,854 |
| Morphine Sulfate ErMorphine Sulfate | 62 | $1,779 |
| Celecoxib | 58 | $1,641 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er | $135 | $16,71723 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 182 pain medicine providers in North Carolina.
Other pain medicine in Morehead City
- James NorthWinston Salem$721K
- Leonardo KapuralWinston Salem$523K
- Christopher GilmoreWinston Salem$457K
- Richard RauckWinston Salem$431K
- Courtney AumanJacksonville$186K
- Jacob WangCharlotte$162K
- Aashish KumarCharlotte$160K
- Javid BakshAsheville$116K
- David ZubLeland$97K
- James DeeringCharlotte$93K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.